Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2024 | Current approaches for managing R/R AL amyloidosis

Jack Khouri • 27 May 2024
ISA 2024
Amyloidosis Rare Diseases Antibodies CAR-T Teclistamab Venetoclax

Jack Khouri, MD, Cleveland Clinic, Cleveland, OH, discusses current approaches for managing patients with relapsed/refractory (R/R) light chain (AL) amyloidosis, both in the transplant-eligible and transplant-ineligible setting. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultancy: Janssen

More from Jack Khouri

Phase II study of burixafor + propranolol + G-CSF for stem cell mobilization in myeloma
4:39
Phase II study of burixafor + propranolol + G-CSF for stem cell mobilization in myeloma
Jack Khouri • 7 Dec 2025
Lisaftoclax combinations in R/R myeloma and AL amyloidosis
2:28
Lisaftoclax combinations in R/R myeloma and AL amyloidosis
Jack Khouri • 5 Sep 2025
Unmet needs in developing immune therapies for amyloidosis & ongoing research in the field
1:18
Unmet needs in developing immune therapies for amyloidosis & ongoing research in the field
Jack Khouri • 5 Sep 2025
An EASIX-based predictive model for CRS and ICANS after CAR-T therapy in RRMM
2:12
An EASIX-based predictive model for CRS and ICANS after CAR-T therapy in RRMM
Jack Khouri • 8 Dec 2024

Related Videos

Tagraxofusp, hyper-CVAD, and venetoclax for patients with BPDCN: Phase II study results
1:40
Tagraxofusp, hyper-CVAD, and venetoclax for patients with BPDCN: Phase II study results
Naveen Pemmaraju • 30 May 2026
How the FDA approval of pivekimab sunirine may shape the field of BPDCN & advice for clinicians
2:20
How the FDA approval of pivekimab sunirine may shape the field of BPDCN & advice for clinicians
Naveen Pemmaraju • 29 May 2026
The importance of alloSCT in improving outcomes for patients with BPDCN
1:40
The importance of alloSCT in improving outcomes for patients with BPDCN
Naveen Pemmaraju • 29 May 2026
First results of LINKER-AL2: linvoseltamab in patients with R/R systemic AL amyloidosis
2:51
First results of LINKER-AL2: linvoseltamab in patients with R/R systemic AL amyloidosis
Hans Lee • 30 May 2026
The content of VJHemOnc is intended for healthcare professionals